泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

Thirty patients with confirmed primary sjogren syndrome and thrombocytopenia during January 2002 and December 2007 were investigated.All the participants received 0.5 mg·kg-1·d-1 Prednisone and 100 ms/d CosA for 1 year.Clinical symptoms and the levels of white blood eell.platelet count,erythrocyte sedimentation rate,liver function,immunoglobin,and rheumatoid factors were recored before and after the treatment.After one-year follow.up,platelet count was elevated(t=11.4179,P< 0.01).There was no significant change in erythrocyte sedimentation rate.The concentrations of immunoglobin and rheumatoid factors were significantly decreased at 1 year(t=5.4222,P<0.01;t= 9.2857.P<0.01).Prednisone plus CosA could effectively treat primary sjOgren syndrome combined with thrombocytopenia and result in fewer side effects.     

泼尼松联合环孢素A治疗干燥综合征合并血小板减少的临床观察

我院2002年1月至2007年12月确诊为干燥综合征的30例患者,均伴有血小板明显减少,维持在（20～50）×10^9/L至少3个月以上。给予泼尼松0．5mg·kg^-1·d^-1及环孢素A100mg／d治疗,疗程1年,观察患者临床症状,定期检测血常规、肝功能、红细胞沉降率、免疫球蛋白、类风湿因子等。结果显示,治疗1年后患者血小板明显升高,由（33±21）×10^9／L升至（115±30）×10^9/L（t=11．4179,P〈0．01）,免疫球蛋白、类风湿因子水平较治疗前明显下降（t值分别为5．4222,9．2857,均P〈0．01）性,红细胞沉降率无明显变化。提示泼尼松联合环孢素A治疗pSS合并顽固性血小板减少的疗效明显,不良反应小。     

对30例原发性干燥综合征合并血小板减少患者的临床研究

目的:对原发性干燥综合征(PSS)患者发生血小板减少的情况进行分析和探讨,并总结治疗效果.方法:对我院2012年1月～2013年3月收治的30例PSS患者的临床资料进行回顾性分析和总结.将其随机分成甲(血小板减少)、乙(无血小板减少)两组,分别为15例.对两组患者的临床特征进行对比和分析.结果:甲组患者发生口眼干燥的例数比乙组少,但甲组发生脾肿大的比例要高于乙组,差异显著,具有统计学意义(P＜0.05).两组患者出现血小板分布的宽度(PDW)、尿蛋白情况、免疫球蛋白A(IgA)比较,甲组要明显高于乙组,差异显著,具有统计学意义(P＜0.05).对甲组患者进行综合治疗以后,14例有效,1例无效.结论:出现血小板减少的PSS患者很容易发生IgA、PDW升高,蛋白尿、PCT下降的现象,但发生口眼干燥的情况比较少.     

激素加环磷酰胺冲击治疗原发性干燥综合征合并肺动脉高压5例

1　临床资料　 1994 0 1/ 2 0 0 2 0 1住院原发性干燥综合征 (pri marySjogren ssyndrome,PSS)患者 4 1例 ,合并肺动脉高压(pulmonaryhypertension ,PHT) 5 (男 1,女 4 )例 ,年龄38～ 6 2(平均 4 7.5 )岁 .PSS的诊断采用欧洲诊断标准 ,并排除其他心肺疾患 .PHT的诊断标准 :UCG或右心导管检查示PASP>3.3kPa.均应用强的松po(起始量 1mg·kg-1·d-1,8wk后减量 ,每周减少原用量的 10 % ,至 5～ 10mg·d-1长期维持) ,并同时给予环磷酰胺冲击治疗 (初始为 8～ 12mg·kg-1·d-1,连续 2d作为 1次冲击 ,每 2wk冲击 1次 ,4次后改为 1mo冲击…     

甲泼尼龙联合泼尼松治疗原发性肾病综合征的疗效分析

目的 分析甲泼尼龙与泼尼松联合治疗原发性肾病综合征的疗效.方法 将90例原发性肾病综合征患者随机分为3组,即口服甲泼尼龙联合泼尼松组(MP+PD组)、口服甲泼尼龙组(MP组)、口服泼尼松组(PD组),进行疗效比较.结果 甲泼尼龙联合泼尼松组完全缓解率优于常规甲泼尼龙组及常规泼尼松组,差异有统计学意义(P＜0.05),在激素相关并发症的减少方面优于泼尼松组(P＜0.05);甲泼尼龙组在激素相关并发症减少方面优于泼尼松组(P＜0.05).结论 甲泼尼龙联合泼尼松治疗原发性肾病综合征较单用能更好地使患者达到 完全缓解,且能减少激素相关并发症.